Mark is a life sciences finance director and chartered management accountant with broad commercial and industry experience.
He is a director of Integral Finance, providing bespoke financial partnering expertise to high growth potential companies, particularly in the knowledge-based life science and technology sectors. Focused mainly on SMEs, Integral’s business advisors take an action orientated approach, drawing upon a broad network of expert associates to help CEOs implement growth strategies, reduce business risk and build management capability.
Previously Mark was the R&D Strategy finance leader at AstraZeneca, where he was responsible for the financial leadership, evaluation and delivery of major change programs, investment decisions relating to early discovery deals and the management of external alliances.
With a customer orientated style that focuses on delivering sustainable value, Mark has a reputation for integrity, transparency, and as an excellent team player.